Skip to main content
Do not take antacids or PPI with mycophenolate. Magnesium & aluminium hydroxide antacids (Maalox) will lower MMF Cma

Dr. John Cush RheumNow

4 years 1 month ago
Do not take antacids or PPI with mycophenolate. Magnesium & aluminium hydroxide antacids (Maalox) will lower MMF Cmax 33% & AUC 17% if given simultaneously. PPI also lowers AUC by ~33% https://t.co/IoWISgL3SY https://t.co/JV1Yv5Pg9d https://t.co/b8UoQ4zMUV https://t.co/VwNgVQ5End
More Bad Safety News for Xeljanz
  • MedPage Today
Another analysis of the mandatory postmarketing safety study for tofacitinib (Xeljanz) has confirmed what most observers expected: that rates of infection with the drug in rheumatoid arthritis are higher than with tumor necrosis factor (TNF) inhibitors.
Evusheld works & reduces COVID-19 by 77%; yet only 25% of available Rx has been used. Its FREE to the ~7000 immunoco

Dr. John Cush RheumNow

4 years 1 month ago
Evusheld works & reduces COVID-19 by 77%; yet only 25% of available Rx has been used. Its FREE to the ~7000 immunocompromised pts who might benefit from it. Repeat doses (300 mg) every 6 mos! Time to jump on this! https://t.co/IzcAUvKoW8 https://t.co/h5q25yWCHG
Study of 57 #RA pts. w/ ILD treated with abatacept. Lung progression in 46% before ABA. After median 27 mos of follow-up

Dr. John Cush RheumNow

4 years 1 month ago
Study of 57 #RA pts. w/ ILD treated with abatacept. Lung progression in 46% before ABA. After median 27 mos of follow-up, ILD - 72% improved or stabilized - 23% worsened - 5% died. No significant change in FVC, DLCO ILD worse assoc w/ DAS28, FVC DLCO https://t.co/kLa61ZS8dt https://t.co/7XhqxcHuCt
Krill Oil Effective in Knee Osteoarthritis

Krill oil supplements in knee OA was shown to be superior to placebo in red

Dr. John Cush RheumNow

4 years 1 month ago
Krill Oil Effective in Knee Osteoarthritis Krill oil supplements in knee OA was shown to be superior to placebo in reducing knee pain, stiffness and function while increasing the omega-3 index. https://t.co/Tx4UnDf5m3 https://t.co/bsh2DQYGc9
Plasmacytoid Dendritic Cell Inhibitor in Cutaneous Lupus

Litifilimab, a humanized monoclonal antibody against BDCA2, t

Dr. John Cush RheumNow

4 years 1 month ago
Plasmacytoid Dendritic Cell Inhibitor in Cutaneous Lupus Litifilimab, a humanized monoclonal antibody against BDCA2, targets the BDCA2 receptor on plasmacytoid dendritic cells. https://t.co/nmadPUhlyH https://t.co/4UbNPMtxIh
Upadacitinib in non-radiographic Axial Spondyloarthritis

The janus kinase inhibitor, upadacitinib, has been shown to s

Dr. John Cush RheumNow

4 years 1 month ago
Upadacitinib in non-radiographic Axial Spondyloarthritis The janus kinase inhibitor, upadacitinib, has been shown to significantly improve the signs and symptoms of nr-AxSpA, extending the efficacy of UPA beyond classic ankylosing spondylitis. https://t.co/IqKdvRkcgZ https://t.co/cieXqJABTL
Approach to ILD in Myositis Syndromes

Mehta et al have published a full read review of managing ILD in patients with in

Dr. John Cush RheumNow

4 years 1 month ago
Approach to ILD in Myositis Syndromes Mehta et al have published a full read review of managing ILD in patients with inflammatory myopathies, a heterogeneous group of syndromes connected by ILD and and increased morbidity and mortality risk. https://t.co/av6fVqASme https://t.co/utHJ9oiyRq
The FDA has extended its indications for ustekinumab (Stelara) for use in pediatric psoriatic arthritis aged 6 years and

Dr. John Cush RheumNow

4 years 1 month ago
The FDA has extended its indications for ustekinumab (Stelara) for use in pediatric psoriatic arthritis aged 6 years and older. Pediatric PsA makes up 6% of all pediatric inflammatory arthritis pts. https://t.co/7bGJ0ZCJJl https://t.co/GtuXdHj3Og
FDA has approved a topical PDE4 inhibitor Roflumilast (Zoryve) a 0.3% cream for use in Plaque Psoriasis (Age 12 and Olde

Dr. John Cush RheumNow

4 years 1 month ago
FDA has approved a topical PDE4 inhibitor Roflumilast (Zoryve) a 0.3% cream for use in Plaque Psoriasis (Age 12 and Older) https://t.co/UwDf3UkuZI https://t.co/5l4xE1LaxA https://t.co/PpwiKYUpdN
#RA disease activity drives risk of hospitalized infections (SIE). Study of 3,254 RA pts w/ 529 hospitalized infx. SIE s

Dr. John Cush RheumNow

4 years 1 month ago
#RA disease activity drives risk of hospitalized infections (SIE). Study of 3,254 RA pts w/ 529 hospitalized infx. SIE seen 3.8/100 person Yrs in remission, 6.6/100PY w/ low Dz activity & 8/100PY w/ moderate Dz activity. HR was 1.60 w/ LDA and 1.83 w/ MDA https://t.co/i4bSsnRiHk https://t.co/kcN9ZvpSOn
PsA Females: more likely to have Peripheral arthritis, have more pain, fatigue, poor function, lower QOL and less likely

Dr. John Cush RheumNow

4 years 1 month ago
PsA Females: more likely to have Peripheral arthritis, have more pain, fatigue, poor function, lower QOL and less likely to have xray damage (than men) Males: more axial dz & severe psoriasis PsA Women may need more psychosocial support & pain management https://t.co/ZYWYu1K3jW https://t.co/xZX913vGdX
QD Clinic - Still's (or Not): an FUO Evaluation

A young man with fever up to 104F, has a complex history.

Is this Sti

Dr. John Cush RheumNow

4 years 1 month ago
QD Clinic - Still's (or Not): an FUO Evaluation A young man with fever up to 104F, has a complex history. Is this Still's disease or not? https://t.co/k47Kz3onCn https://t.co/UVMaaU1uPO
521 clinically suspect arthralgia (CSA) pts were assessed - Low educational attainment was associated with increased ris

Dr. John Cush RheumNow

4 years 1 month ago
521 clinically suspect arthralgia (CSA) pts were assessed - Low educational attainment was associated with increased risk of developing inflammatory arthritis (HR = 2.35), independent of BMI & smoking https://t.co/h1bXDfxaQk https://t.co/g2ign0HDmj
Evusheld works & reduces COVID-19 by 77%; yet only 25% of available Rx has been used. Its FREE to the ~7000 immunoco

Dr. John Cush RheumNow

4 years 1 month ago
Evusheld works & reduces COVID-19 by 77%; yet only 25% of available Rx has been used. Its FREE to the ~7000 immunocompromised pts who might benefit from it. Repeat doses (300 mg) every 6 mos! Time to jump on this! https://t.co/BSi7EtJytf https://t.co/GafjXXZ2ny
×